Fluorescent treponemal antibody absorption test information

This article needs more reliable medical references for verification or relies too heavily on primary sources. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed. Find sources: "Fluorescent treponemal antibody absorption test" – news · newspapers · books · scholar · JSTOR (November 2021)

The fluorescent treponemal antibody absorption (FTA-ABS) test is a diagnostic test for syphilis. Using antibodies specific for the Treponema pallidum species, such tests would be assumed to be more specific than non-treponemal testing such as VDRL but have been shown repeatedly to be sensitive but not specific for the diagnosis of neurosyphilis in cerebrospinal fluid (CSF). In addition, FTA-ABS turns positive earlier and remains positive longer than VDRL. Other treponemes, such as T. pertenue, may also produce a positive FTA-ABS. The ABS suffix refers particularly to a processing step used to remove nonspecific antispirochetal antibodies present in normal serum.

In general, the test has two roles:

1. As a confirmatory test for a positive result from a serum screening test (RPR for example).
2. Since the test has high negative predictive value it is very useful in both serum or CSF to exclude/rule out neurosyphilis if the FTA test result is negative. " A negative FTA in serum excludes neurosyphilis".